Pretreatment 18F ‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Intra-tumoral heterogeneity of 18F ‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneit...

Source: Cancer Imaging - September 19, 2023 Category: Radiology Authors: Guang Ma, Shuhui You, Yizhao Xie, Bingxin Gu, Cheng Liu, Xichun Hu, Shaoli Song, Biyun wang and Zhongyi Yang Tags: Research article Source Type: research